NCT01074619

Study on Cognitive Disorders of Multiple Sclerosis

Effects of Memantine on Cognitive Disorders of Relapsing-remitting Multiple Sclerosis

• Status: Completed
• Phase: Phase 3
• Study type: Interventional
• Enrollment: 90 (actual)
• Sponsor: University Hospital, Caen · Academic / Other
• Sex: All
• Age: 18 Years – 60 Years
• Healthy volunteers: Not accepted

Summary

The purpose of this study is to determine if memantine is effective in the treatment on cognitive disorders of Relapsing - Remitting multiple sclerosis. m

Conditions

• Multiple Sclerosis

Interventions

Type	Name	Description
DRUG	Memantine	5 mg the first week, then 10 mg the second week, 15 mg the third week and finally 20 mg the fourth week until the end of the study (t0 + 1 year)
DRUG	Placebo	5 mg the first week, then 10 mg the second week, 15 mg the third week and finally 20 mg the fourth week until the end of the study (t0 + 1 year)

Timeline

• Start date: 2005-09-01
• Primary completion: 2011-03-01
• Completion: 2011-11-01
• First posted: 2010-02-24
• Last updated: 2012-09-03

Locations

1 site across 1 country: France